Forbes February 8, 2024
Jill Collins, CEO, Chief Strategy Officer, Audacity Health.
It’s been a volatile few years in the healthcare and biotech space. In 2020, the Covid-19 pandemic created massive growth from investment in healthcare. By 2022, as the pandemic waned, biotech took a tumble, marked by slashed budgets, massively reduced head counts and cautious financial stewardship. The pandemic officially ended on May 11, 2023, and we are still waiting to see what the future holds. As we move further into 2024, the biotech and healthcare markets are starting to win back their optimism. Here is my forecast for 2024.
Companies will value efficiency over novelty.
The R&D and marketing budgets we saw during the pandemic are gone, and they are likely not...
Today's Sponsors
Today's Sponsor